Skip to main content

Day: May 7, 2025

Intchains Group Limited to Report Unaudited First Quarter 2025 Financial Results on Thursday, May 22, 2025

SINGAPORE, May 07, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies, and the active development of innovative Web3 applications, today announced that it will release its unaudited financial results for the first quarter of 2025 ended March 31, 2025. Conference Call Information The Company’s management team will host an earnings conference call to discuss its financial results at 8:00 PM U.S. Eastern Time on May 22, 2025 (8:00 AM Beijing Time on May 23, 2025). Details for the conference call are as follows:Event Title: Intchains Group Limited First Quarter 2025 Earnings Conference CallDate: May 22, 2025Time: 8:00 PM U.S. Eastern TimeRegistration...

Continue reading

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar’s late-breaker poster presentation is available at the following link: https://www.monopartx.com/pipeline/ALXN1840/EASL-poster-may-2025. The poster supports the potential use of ALXN1840 as a therapeutic option for Wilson disease, a rare and progressive genetic condition in which the body’s pathway for removing excess...

Continue reading

CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF EUR 750,000,000 Subordinated Fixed Rate Resettable Notes issued on June 5, 2020 (ISIN: FR0013516184)

Montrouge, May 7, 2025 CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF EUR 750,000,000 Subordinated Fixed Rate Resettable Notes issued on June 5, 2020 (ISIN: FR0013516184)* Crédit Agricole S.A. (the “Issuer”) announces today the redemption (the “Redemption”) with effect on June 5, 2025 (the “Redemption Date”) of all of its outstanding EUR 750,000,000 Subordinated Fixed Rate Resettable Notes issued on June 5, 2020 (ISIN: FR0013516184) (the “Notes”) pursuant to Condition 6(e) (Redemption at the Option of the Issuer) of the terms and conditions of the Notes (the “Terms and Conditions”) included in the base prospectus dated April 9, 2020, which was granted the visa n°20-136 by the Autorité des marchés financiers on April 9, 2020 (as further amended and supplemented, the “Base Prospectus”) at the outstanding nominal amount thereof, together with...

Continue reading

Suominen Corporation’s Interim Report for January 1 – March 31, 2025: Navigating a challenging environment

Suominen Corporation’s Interim Report on May 7, 2025, at 9:30 a.m. (EEST) Suominen Corporation’s Interim Report for January 1 – March 31, 2025: Navigating a challenging environment KEY FIGURES  1-3/ 1-3/ 1-12/  2025 2024 2024Net sales, EUR million 117.5 113.6 462.3Comparable EBITDA, EUR million 4.1 4.5 17.0Comparable EBITDA, % 3.5 3.9 3.7EBITDA, EUR million 4.1 4.7 17.2EBITDA, % 3.5 4.1 3.7Comparable operating profit, EUR million -0.3 -0.1 -1.4Comparable operating profit, % -0.2 -0.1 -0.3Operating profit, EUR million -0.3 0.1 -1.3Operating profit, % -0.2 0.1 -0.3Profit for the period, EUR million -2.2 -1.0 -5.3Cash flow from operations, EUR million -0.4 -2.2 3.9Cash flow from operations per share, EUR -0.01 -0.04 0.07Earnings per share, basic, EUR -0.04 0.02 -0.09Return on invested capital,...

Continue reading

Karolinska Development’s portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 2025

STOCKHOLM, SWEDEN – May 7, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will attend the EASL Congress 2025 in Amsterdam, May 7–10, to present validation and implementation data for the newly developed clinical scale for Primary Biliary Cholangitis, PBC. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company’s drug candidate golexanolone is currently being evaluated in a clinical Phase 2a study in PBC. At EASL 2025 (European Association for the Study of the Liver), Umecrine Cognition will present validation and implementation data for the newly developed clinical scale CGI-S-PBC™ (Clinical Global Impression of Severity Scale for Primary Biliary Cholangitis), which was partly developed...

Continue reading

Inside information: Suominen announces a cost saving program to secure profitable growth

Suominen Corporation, inside information, May 7, 2025 at 9:35 a.m. (EEST) Suominen announces a cost-saving program to secure profitable growth and ensure long-term competitiveness. “We are launching a cost saving program to address our structural costs across operations and global functions to secure profitable growth. This is a necessary step to improve our competitiveness and profitability, as we continue investing in innovation and sustainability, collaborating closely with our customers,” says President & CEO Tommi Björnman. The program is expected to result in savings of approximately EUR 10 million. Savings are planned to realize over the next 24 months. The saving program is expected to affect up to 60 positions globally, subject to local consultation procedures. SUOMINEN CORPORATION For further information:Tommi Björnman,...

Continue reading

Sydbank’s Interim Report – Q1 2025

Company Announcement No 20/20257 May 2025 Sydbank’s Interim Report – Q1 2025 Q1 2025 – highlightsProfit for the period of DKK 645m equals a return on equity of 17.4% p.a. after tax Core income of DKK 1,700m is 8% lower compared to the same period in 2024 Trading income of DKK 64m compared to DKK 89m in the same period in 2024 Costs (core earnings) of DKK 881m compared to DKK 831m in the same period in 2024 Core earnings before impairment of DKK 883m are 20% lower compared to the same period in 2024 Impairment charges for loans and advances etc represent an expense of DKK 35m Bank loans and advances have gone down by DKK 1.2bn, equal to a decrease of 2% compared to year-end 2024 The CET1 ratio stands at 16.3%, equal to a decline of 1.5pp compared to year-end 2024CEO Mark Luscombe comments on the result:It is positive that we have...

Continue reading

OP Corporate Bank plc’s Interim Report 1 January–31 March 2025

OP Corporate Bank plcInterim Report 1 January–31 March 2025Stock Exchange Release 7 May 2025 at 9.00 am EEST OP Corporate Bank plc’s Interim Report 1 January–31 March 2025OP Corporate Bank plc’s operating profit rose to EUR 140 million (112). Total income grew by 10% to EUR 215 million (196). Net interest income, EUR 157 million, remained at the previous year’s level (157). Investment income increased to EUR 24 million (9). Net commissions and fees decreased by 14% to EUR 17 million (19). Other operating income increased to EUR 17 million (11). Impairment loss on receivables decreased to EUR 1 million (12). Total operating expenses increased by 3% to EUR 73 million (71). The cost/income ratio improved to 34% (36). The loan portfolio grew by 1.4% to EUR 28.2 billion (27.8) year on year. The deposit portfolio increased...

Continue reading

Agillic releases Q1 2025 financial results: YoY, ARR from subscriptions is up 4%, EBITDA is up DKK 0.2 million, and cash flow from operations improved by DKK 1.9 million

Announcement no. 08 – Copenhagen, 7 May 2025 – Agillic A/S ARR from subscriptions increased by 4% in Q1 2025 vs. Q1 2024 due to new clients and stabilisation of churn. Agillic expects growth from both existing clients and new clients in 2025. Total revenue decreased by 1% in Q1 2025 YoY due to lower revenue following last year’s high churn level. Total revenue is expected to increase in 2025 as per 2025 guidance. EBITDA increased by 20% in Q1 2025 vs. Q1 2024. The increase is driven by reduced employee costs following the organisational changes in Q4 2024. Cash flow from operations was DKK 1.9 million in Q1 2025, an increase of DKK 1.9 million YoY. The improved cash flow derives from a positive development in working capital. Key financial and SaaS highlights(DKK million)Income statement Q1 2025 Q1 2024 Change ...

Continue reading

Harvia’s Interim Report 1 January – 31 March 2025

Harvia Plc, Interim report 7 May 2025 at 9:00 a.m. EESTHarvia Q1 2025: Strong profitability – growth in all regions This release is a summary of Harvia Plc’s Interim Report January–March 2025. The complete report is attached to this release as a pdf file. It is also available on Harvia’s website at https://harviagroup.com/. Highlights of the review period January–March 2025:Revenue increased by 22.7% to EUR 52.0 million (42.4). At comparable exchange rates, revenue increased by 21.4% to EUR 51.4 million. Organic revenue growth was 14.1%. Operating profit was EUR 11.9 million (9.9), making up 22.9% (23.3%) of the revenue. Adjusted operating profit was EUR 11.9 million (10.1), making up 22.9% (23.8%) of the revenue. At comparable exchange rates, the adjusted operating profit was EUR 11.9 million (23.1% of the revenue). Operating free...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.